Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor

The pyridine derivative cerivastatin is a new entirely synthetic and enantiomerically pure inhibitor of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase. As a sodium salt cerivastatin is present in the active, open ring form. Cerivastatin inhibited the membrane-bound (non-solubilized) HMG-CoA redu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Atherosclerosis 1997-11, Vol.135 (1), p.119-130
Hauptverfasser: Bischoff, Hilmar, Angerbauer, Rolf, Bender, Joachim, Bischoff, Erwin, Faggiotto, Agostino, Petzinna, Dieter, Pfitzner, Jörg, Porter, Michael C, Schmidt, Delf, Thomas, Günter
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 130
container_issue 1
container_start_page 119
container_title Atherosclerosis
container_volume 135
creator Bischoff, Hilmar
Angerbauer, Rolf
Bender, Joachim
Bischoff, Erwin
Faggiotto, Agostino
Petzinna, Dieter
Pfitzner, Jörg
Porter, Michael C
Schmidt, Delf
Thomas, Günter
description The pyridine derivative cerivastatin is a new entirely synthetic and enantiomerically pure inhibitor of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase. As a sodium salt cerivastatin is present in the active, open ring form. Cerivastatin inhibited the membrane-bound (non-solubilized) HMG-CoA reductase of the native microsomal fraction isolated from rat liver with a K i value of 1.3×10 −9 M. The reference compound lovastatin was 100-fold less potent and exhibited a K i value of 150×10 −9 M. Cerivastatin inhibited the cholesterol synthesis in the human hepatoma cell line HepG2 cells with a similar IC 50 value of 1.0×10 −9 M. In vivo studies reflected its high in vitro activity. In both rats and dogs, cerivastatin inhibited the hepatic [ 14C]cholesterol synthesis from [ 14C]acetate with an oral ED 50 value of 0.002 mg/kg body weight, while lovastatin exhibited an oral ED 50 value of 0.3 mg/kg in rats, showing again the ratio of 100 or more between cerivastatin and lovastatin. In the small intestine and testes, cerivastatin was at least 50-fold less active with oral ED 50 values higher than 0.1 mg/kg, which is indicative for a high liver selectivity of cerivastatin. In cholestyramine-primed dogs cerivastatin dose-dependently lowered the serum cholesterol concentrations by up to 59% with 0.1 mg/kg after 20 days. Interestingly, the serum triglycerides were markedly reduced by 53 and 76% with 0.03 and 0.1 mg/kg, respectively. In normal chow fed dogs the low density lipoprotein (LDL) concentrations were reduced by up to 75% after 0.1 mg cerivastatin/kg. The ratio of HDL/LDL increased by 81% compared with a change of only 14% in the placebo treated control group. The antiatherogenic effect of cerivastatin was shown in rabbits fed a diet enriched with 0.2% cholesterol. After 9 weeks on diet 0.1 mg cerivastatin/kg decreased the accumulation of cholesterol ester in the arterial tissue by 73%. In summary, these data as compared to published data on other HMG-CoA reductase inhibitors demonstrate cerivastatin to be the most active compound in this class. Vastatins used in therapy are effective in mg doses, while cerivastatin offers a new low dose therapy in the μg range.
doi_str_mv 10.1016/S0021-9150(97)00188-3
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79439600</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0021915097001883</els_id><sourcerecordid>79439600</sourcerecordid><originalsourceid>FETCH-LOGICAL-c509t-efe57bdbb44ed47962307f22f49f007b239eea88f1aa4831d2657a2bc8661dcc3</originalsourceid><addsrcrecordid>eNqFkMFuEzEQhi0EKqHwCJV8QAgOC2Ovd21zQVUELVIRB-CILK897hpt1sF2IuXt2TZRrpzm8H__zOgj5IrBewas__ADgLNGsw7eavkOgCnVtE_IiimpGyaUeEpWZ-Q5eVHKHwAQkqkLcqFb3XEFK_J7jTnubam2xvkj3Y42b6xLU7o_0BSopXPa40TLYa4j1uionT0d4_04Hah1Ne6R3n67adbpmmb0O1dtQRrnMQ6xpvySPAt2KvjqNC_Jry-ff65vm7vvN1_X13eN60DXBgN2cvDDIAR6IXXPW5CB8yB0AJADbzWiVSowa4Vqmed9Jy0fnOp75p1rL8mb495tTn93WKrZxOJwmuyMaVeM1KLVPcACdkfQ5VRKxmC2OW5sPhgG5kGredRqHpwZLc2jVtMuvavTgd2wQX9unTwu-etTbouzU8h2drGcMQ4dY5Iv2KcjhouMfcRsios4O_Qxo6vGp_ifR_4BodyUYw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79439600</pqid></control><display><type>article</type><title>Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Bischoff, Hilmar ; Angerbauer, Rolf ; Bender, Joachim ; Bischoff, Erwin ; Faggiotto, Agostino ; Petzinna, Dieter ; Pfitzner, Jörg ; Porter, Michael C ; Schmidt, Delf ; Thomas, Günter</creator><creatorcontrib>Bischoff, Hilmar ; Angerbauer, Rolf ; Bender, Joachim ; Bischoff, Erwin ; Faggiotto, Agostino ; Petzinna, Dieter ; Pfitzner, Jörg ; Porter, Michael C ; Schmidt, Delf ; Thomas, Günter</creatorcontrib><description>The pyridine derivative cerivastatin is a new entirely synthetic and enantiomerically pure inhibitor of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase. As a sodium salt cerivastatin is present in the active, open ring form. Cerivastatin inhibited the membrane-bound (non-solubilized) HMG-CoA reductase of the native microsomal fraction isolated from rat liver with a K i value of 1.3×10 −9 M. The reference compound lovastatin was 100-fold less potent and exhibited a K i value of 150×10 −9 M. Cerivastatin inhibited the cholesterol synthesis in the human hepatoma cell line HepG2 cells with a similar IC 50 value of 1.0×10 −9 M. In vivo studies reflected its high in vitro activity. In both rats and dogs, cerivastatin inhibited the hepatic [ 14C]cholesterol synthesis from [ 14C]acetate with an oral ED 50 value of 0.002 mg/kg body weight, while lovastatin exhibited an oral ED 50 value of 0.3 mg/kg in rats, showing again the ratio of 100 or more between cerivastatin and lovastatin. In the small intestine and testes, cerivastatin was at least 50-fold less active with oral ED 50 values higher than 0.1 mg/kg, which is indicative for a high liver selectivity of cerivastatin. In cholestyramine-primed dogs cerivastatin dose-dependently lowered the serum cholesterol concentrations by up to 59% with 0.1 mg/kg after 20 days. Interestingly, the serum triglycerides were markedly reduced by 53 and 76% with 0.03 and 0.1 mg/kg, respectively. In normal chow fed dogs the low density lipoprotein (LDL) concentrations were reduced by up to 75% after 0.1 mg cerivastatin/kg. The ratio of HDL/LDL increased by 81% compared with a change of only 14% in the placebo treated control group. The antiatherogenic effect of cerivastatin was shown in rabbits fed a diet enriched with 0.2% cholesterol. After 9 weeks on diet 0.1 mg cerivastatin/kg decreased the accumulation of cholesterol ester in the arterial tissue by 73%. In summary, these data as compared to published data on other HMG-CoA reductase inhibitors demonstrate cerivastatin to be the most active compound in this class. Vastatins used in therapy are effective in mg doses, while cerivastatin offers a new low dose therapy in the μg range.</description><identifier>ISSN: 0021-9150</identifier><identifier>EISSN: 1879-1484</identifier><identifier>DOI: 10.1016/S0021-9150(97)00188-3</identifier><identifier>PMID: 9395280</identifier><language>eng</language><publisher>Amsterdam: Elsevier Ireland Ltd</publisher><subject>Administration, Oral ; Adrenal Glands - drug effects ; Animals ; Arteriosclerosis - prevention &amp; control ; Atherosclerosis ; Biological and medical sciences ; Cell Line ; Dogs ; Female ; General and cellular metabolism. Vitamins ; HMG-CoA-reductase inhibition ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - isolation &amp; purification ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - metabolism ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology ; Hypolipidemic Agents - administration &amp; dosage ; Intestine, Small - drug effects ; Male ; Medical sciences ; Organ Specificity - drug effects ; Pharmacology. Drug treatments ; Pyridines - administration &amp; dosage ; Pyridines - pharmacology ; Rabbits ; Rats ; Rats, Inbred Strains ; Rats, Wistar ; Stereoisomerism ; Testis - drug effects ; Tissue selectivity</subject><ispartof>Atherosclerosis, 1997-11, Vol.135 (1), p.119-130</ispartof><rights>1997 Elsevier Science Ireland Ltd</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c509t-efe57bdbb44ed47962307f22f49f007b239eea88f1aa4831d2657a2bc8661dcc3</citedby><cites>FETCH-LOGICAL-c509t-efe57bdbb44ed47962307f22f49f007b239eea88f1aa4831d2657a2bc8661dcc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0021-9150(97)00188-3$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,780,784,789,790,3548,23929,23930,25139,27923,27924,45994</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2051172$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9395280$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bischoff, Hilmar</creatorcontrib><creatorcontrib>Angerbauer, Rolf</creatorcontrib><creatorcontrib>Bender, Joachim</creatorcontrib><creatorcontrib>Bischoff, Erwin</creatorcontrib><creatorcontrib>Faggiotto, Agostino</creatorcontrib><creatorcontrib>Petzinna, Dieter</creatorcontrib><creatorcontrib>Pfitzner, Jörg</creatorcontrib><creatorcontrib>Porter, Michael C</creatorcontrib><creatorcontrib>Schmidt, Delf</creatorcontrib><creatorcontrib>Thomas, Günter</creatorcontrib><title>Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor</title><title>Atherosclerosis</title><addtitle>Atherosclerosis</addtitle><description>The pyridine derivative cerivastatin is a new entirely synthetic and enantiomerically pure inhibitor of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase. As a sodium salt cerivastatin is present in the active, open ring form. Cerivastatin inhibited the membrane-bound (non-solubilized) HMG-CoA reductase of the native microsomal fraction isolated from rat liver with a K i value of 1.3×10 −9 M. The reference compound lovastatin was 100-fold less potent and exhibited a K i value of 150×10 −9 M. Cerivastatin inhibited the cholesterol synthesis in the human hepatoma cell line HepG2 cells with a similar IC 50 value of 1.0×10 −9 M. In vivo studies reflected its high in vitro activity. In both rats and dogs, cerivastatin inhibited the hepatic [ 14C]cholesterol synthesis from [ 14C]acetate with an oral ED 50 value of 0.002 mg/kg body weight, while lovastatin exhibited an oral ED 50 value of 0.3 mg/kg in rats, showing again the ratio of 100 or more between cerivastatin and lovastatin. In the small intestine and testes, cerivastatin was at least 50-fold less active with oral ED 50 values higher than 0.1 mg/kg, which is indicative for a high liver selectivity of cerivastatin. In cholestyramine-primed dogs cerivastatin dose-dependently lowered the serum cholesterol concentrations by up to 59% with 0.1 mg/kg after 20 days. Interestingly, the serum triglycerides were markedly reduced by 53 and 76% with 0.03 and 0.1 mg/kg, respectively. In normal chow fed dogs the low density lipoprotein (LDL) concentrations were reduced by up to 75% after 0.1 mg cerivastatin/kg. The ratio of HDL/LDL increased by 81% compared with a change of only 14% in the placebo treated control group. The antiatherogenic effect of cerivastatin was shown in rabbits fed a diet enriched with 0.2% cholesterol. After 9 weeks on diet 0.1 mg cerivastatin/kg decreased the accumulation of cholesterol ester in the arterial tissue by 73%. In summary, these data as compared to published data on other HMG-CoA reductase inhibitors demonstrate cerivastatin to be the most active compound in this class. Vastatins used in therapy are effective in mg doses, while cerivastatin offers a new low dose therapy in the μg range.</description><subject>Administration, Oral</subject><subject>Adrenal Glands - drug effects</subject><subject>Animals</subject><subject>Arteriosclerosis - prevention &amp; control</subject><subject>Atherosclerosis</subject><subject>Biological and medical sciences</subject><subject>Cell Line</subject><subject>Dogs</subject><subject>Female</subject><subject>General and cellular metabolism. Vitamins</subject><subject>HMG-CoA-reductase inhibition</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - isolation &amp; purification</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - metabolism</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</subject><subject>Hypolipidemic Agents - administration &amp; dosage</subject><subject>Intestine, Small - drug effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Organ Specificity - drug effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyridines - administration &amp; dosage</subject><subject>Pyridines - pharmacology</subject><subject>Rabbits</subject><subject>Rats</subject><subject>Rats, Inbred Strains</subject><subject>Rats, Wistar</subject><subject>Stereoisomerism</subject><subject>Testis - drug effects</subject><subject>Tissue selectivity</subject><issn>0021-9150</issn><issn>1879-1484</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMFuEzEQhi0EKqHwCJV8QAgOC2Ovd21zQVUELVIRB-CILK897hpt1sF2IuXt2TZRrpzm8H__zOgj5IrBewas__ADgLNGsw7eavkOgCnVtE_IiimpGyaUeEpWZ-Q5eVHKHwAQkqkLcqFb3XEFK_J7jTnubam2xvkj3Y42b6xLU7o_0BSopXPa40TLYa4j1uionT0d4_04Hah1Ne6R3n67adbpmmb0O1dtQRrnMQ6xpvySPAt2KvjqNC_Jry-ff65vm7vvN1_X13eN60DXBgN2cvDDIAR6IXXPW5CB8yB0AJADbzWiVSowa4Vqmed9Jy0fnOp75p1rL8mb495tTn93WKrZxOJwmuyMaVeM1KLVPcACdkfQ5VRKxmC2OW5sPhgG5kGredRqHpwZLc2jVtMuvavTgd2wQX9unTwu-etTbouzU8h2drGcMQ4dY5Iv2KcjhouMfcRsios4O_Qxo6vGp_ifR_4BodyUYw</recordid><startdate>19971101</startdate><enddate>19971101</enddate><creator>Bischoff, Hilmar</creator><creator>Angerbauer, Rolf</creator><creator>Bender, Joachim</creator><creator>Bischoff, Erwin</creator><creator>Faggiotto, Agostino</creator><creator>Petzinna, Dieter</creator><creator>Pfitzner, Jörg</creator><creator>Porter, Michael C</creator><creator>Schmidt, Delf</creator><creator>Thomas, Günter</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19971101</creationdate><title>Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor</title><author>Bischoff, Hilmar ; Angerbauer, Rolf ; Bender, Joachim ; Bischoff, Erwin ; Faggiotto, Agostino ; Petzinna, Dieter ; Pfitzner, Jörg ; Porter, Michael C ; Schmidt, Delf ; Thomas, Günter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c509t-efe57bdbb44ed47962307f22f49f007b239eea88f1aa4831d2657a2bc8661dcc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Administration, Oral</topic><topic>Adrenal Glands - drug effects</topic><topic>Animals</topic><topic>Arteriosclerosis - prevention &amp; control</topic><topic>Atherosclerosis</topic><topic>Biological and medical sciences</topic><topic>Cell Line</topic><topic>Dogs</topic><topic>Female</topic><topic>General and cellular metabolism. Vitamins</topic><topic>HMG-CoA-reductase inhibition</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - isolation &amp; purification</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - metabolism</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</topic><topic>Hypolipidemic Agents - administration &amp; dosage</topic><topic>Intestine, Small - drug effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Organ Specificity - drug effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyridines - administration &amp; dosage</topic><topic>Pyridines - pharmacology</topic><topic>Rabbits</topic><topic>Rats</topic><topic>Rats, Inbred Strains</topic><topic>Rats, Wistar</topic><topic>Stereoisomerism</topic><topic>Testis - drug effects</topic><topic>Tissue selectivity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bischoff, Hilmar</creatorcontrib><creatorcontrib>Angerbauer, Rolf</creatorcontrib><creatorcontrib>Bender, Joachim</creatorcontrib><creatorcontrib>Bischoff, Erwin</creatorcontrib><creatorcontrib>Faggiotto, Agostino</creatorcontrib><creatorcontrib>Petzinna, Dieter</creatorcontrib><creatorcontrib>Pfitzner, Jörg</creatorcontrib><creatorcontrib>Porter, Michael C</creatorcontrib><creatorcontrib>Schmidt, Delf</creatorcontrib><creatorcontrib>Thomas, Günter</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Atherosclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bischoff, Hilmar</au><au>Angerbauer, Rolf</au><au>Bender, Joachim</au><au>Bischoff, Erwin</au><au>Faggiotto, Agostino</au><au>Petzinna, Dieter</au><au>Pfitzner, Jörg</au><au>Porter, Michael C</au><au>Schmidt, Delf</au><au>Thomas, Günter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor</atitle><jtitle>Atherosclerosis</jtitle><addtitle>Atherosclerosis</addtitle><date>1997-11-01</date><risdate>1997</risdate><volume>135</volume><issue>1</issue><spage>119</spage><epage>130</epage><pages>119-130</pages><issn>0021-9150</issn><eissn>1879-1484</eissn><abstract>The pyridine derivative cerivastatin is a new entirely synthetic and enantiomerically pure inhibitor of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase. As a sodium salt cerivastatin is present in the active, open ring form. Cerivastatin inhibited the membrane-bound (non-solubilized) HMG-CoA reductase of the native microsomal fraction isolated from rat liver with a K i value of 1.3×10 −9 M. The reference compound lovastatin was 100-fold less potent and exhibited a K i value of 150×10 −9 M. Cerivastatin inhibited the cholesterol synthesis in the human hepatoma cell line HepG2 cells with a similar IC 50 value of 1.0×10 −9 M. In vivo studies reflected its high in vitro activity. In both rats and dogs, cerivastatin inhibited the hepatic [ 14C]cholesterol synthesis from [ 14C]acetate with an oral ED 50 value of 0.002 mg/kg body weight, while lovastatin exhibited an oral ED 50 value of 0.3 mg/kg in rats, showing again the ratio of 100 or more between cerivastatin and lovastatin. In the small intestine and testes, cerivastatin was at least 50-fold less active with oral ED 50 values higher than 0.1 mg/kg, which is indicative for a high liver selectivity of cerivastatin. In cholestyramine-primed dogs cerivastatin dose-dependently lowered the serum cholesterol concentrations by up to 59% with 0.1 mg/kg after 20 days. Interestingly, the serum triglycerides were markedly reduced by 53 and 76% with 0.03 and 0.1 mg/kg, respectively. In normal chow fed dogs the low density lipoprotein (LDL) concentrations were reduced by up to 75% after 0.1 mg cerivastatin/kg. The ratio of HDL/LDL increased by 81% compared with a change of only 14% in the placebo treated control group. The antiatherogenic effect of cerivastatin was shown in rabbits fed a diet enriched with 0.2% cholesterol. After 9 weeks on diet 0.1 mg cerivastatin/kg decreased the accumulation of cholesterol ester in the arterial tissue by 73%. In summary, these data as compared to published data on other HMG-CoA reductase inhibitors demonstrate cerivastatin to be the most active compound in this class. Vastatins used in therapy are effective in mg doses, while cerivastatin offers a new low dose therapy in the μg range.</abstract><cop>Amsterdam</cop><pub>Elsevier Ireland Ltd</pub><pmid>9395280</pmid><doi>10.1016/S0021-9150(97)00188-3</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0021-9150
ispartof Atherosclerosis, 1997-11, Vol.135 (1), p.119-130
issn 0021-9150
1879-1484
language eng
recordid cdi_proquest_miscellaneous_79439600
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Administration, Oral
Adrenal Glands - drug effects
Animals
Arteriosclerosis - prevention & control
Atherosclerosis
Biological and medical sciences
Cell Line
Dogs
Female
General and cellular metabolism. Vitamins
HMG-CoA-reductase inhibition
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - isolation & purification
Hydroxymethylglutaryl-CoA Reductase Inhibitors - metabolism
Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
Hypolipidemic Agents - administration & dosage
Intestine, Small - drug effects
Male
Medical sciences
Organ Specificity - drug effects
Pharmacology. Drug treatments
Pyridines - administration & dosage
Pyridines - pharmacology
Rabbits
Rats
Rats, Inbred Strains
Rats, Wistar
Stereoisomerism
Testis - drug effects
Tissue selectivity
title Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T14%3A13%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cerivastatin:%20pharmacology%20of%20a%20novel%20synthetic%20and%20highly%20active%20HMG-CoA%20reductase%20inhibitor&rft.jtitle=Atherosclerosis&rft.au=Bischoff,%20Hilmar&rft.date=1997-11-01&rft.volume=135&rft.issue=1&rft.spage=119&rft.epage=130&rft.pages=119-130&rft.issn=0021-9150&rft.eissn=1879-1484&rft_id=info:doi/10.1016/S0021-9150(97)00188-3&rft_dat=%3Cproquest_cross%3E79439600%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79439600&rft_id=info:pmid/9395280&rft_els_id=S0021915097001883&rfr_iscdi=true